BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

IDM, Inc. 

9 Parker

Irvine  California  92618-1605  U.S.A.
Phone: 949-470-4751 Fax: 949-470-6470


SEARCH JOBS










 Company News
Epimmune Inc. (EPMN) And IDM S.A. Agree To Combine Businesses 10/19/2005 5:13:01 PM    More...
Immuno-Designed Molecules Signs An R&D Agreement On Anti-Cancer Vaccine With The Walter Reed Army Institute of Research 10/19/2005 5:12:06 PM    More...
The FDA Has Authorized IDM, Inc. To Start A Phase II Trial In The United States On Its Therapeutic Vaccine Uvidem 10/19/2005 5:11:36 PM    More...
IDM, Inc. Announces The Opening Of Its cGMP Production Center In The United States 10/19/2005 5:10:58 PM    More...
IDM S.A. Will Present Phase II Trial Results For Its Melanoma Cancer Vaccine, Uvidem, At American Society of Clinical Oncology - Orlando - On May 15, 2005 10/19/2005 5:10:30 PM    More...
IDM, Inc. Announces Detailed Phase III Results For Mepact In Osteosarcoma To Be Presented At ASPHO Annual Meeting 10/19/2005 5:10:20 PM    More...
IDM, Inc. Obtains A European Patent Protecting The Basic Technology Behind Its Therapeutic Vaccines 10/19/2005 5:09:50 PM    More...
IDM And Cambridge Laboratories Limited Sign An Exclusive Marketing Agreement For Junovan(TM) (Mepact) In The United Kingdom And Ireland 10/19/2005 5:09:19 PM    More...
Mepact, IDM, Inc.'s Most Advanced Product, Receives "Orphan Medicinal Product" Designation For The Treatment Of Osteosarcoma In The European Union 10/19/2005 5:08:58 PM    More...
IDM, Inc. Announces Appointment Of Guy-Charles Fanneau de la Horie As Vice-President, Director France 10/19/2005 5:08:56 PM    More...